1 patient evaluation for ALS Phase 2 Study KNS-760704 CL201

Oct 24, 2009 (Started Jul 01, 2008)

  • Effectiveness
    Major (for Participate in clinical trial)
  • Effectiveness
    Can't tell (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Somewhat hard to take
Dosage: 300 mg Daily
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost: < $25 monthly

  • 4 helpful marks
Last updated:
Showing 1 of 1 patient evaluation for ALS Phase 2 Study KNS-760704 CL201